Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Tresukosol, Damrus ^a   Suktitipat, Bhoom ^a,b   Hunnangkul, Saowalak ^a   Kamkaew, Ruttakarn ^a   Poldee, Saiphon ^a   Tassaneetrithep, Boonrat ^a   Likidlilid, Atip ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYTOCHROME P450 2C19; ANTITHROMBOCYTIC AGENT; ARYLDIALKYLPHOSPHATASE; CYP2C19 PROTEIN, HUMAN; TICLOPIDINE;

ADULT; AGED; ALLELE; ANTIPLATELET RESPONSE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYP2C19 GENE; DIABETES MELLITUS; DRUG RESISTANCE; EPISTASIS; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PON1 GENE; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SMOKING; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE KINETICS; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENZYMOLOGY; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; CORONARY ARTERY DISEASE; CYTOCHROME P-450 CYP2C19; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 84908211522     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110188     Document Type: Article

References (57)

1. Moleerergpoom W, Kanjanavanit R, Jintapakorn W, Sritara P (2007) Costs of payment in Thai acute coronary syndrome patients. J Med Assoc Thai 90 Suppl 1: 21-31.
2. Syed FA, Bett J, Walters DL (2011) Anti-platelet therapy for Acute Coronary Syndrome: A review of currently available agents and what the future holds. Cardiovasc Hematol Disord Drug Targets.
3. Smith SC, Jr., Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, et al. (2006) ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47: 216-235.
4. Gurbel PA, Tantry US (2006) Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 3: 387-395.
5. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107: 2908-2913.
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, et al. (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49: 1505-1516.
7. Jaremo P, Lindahl TL, Fransson SG, Richter A (2002) Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252: 233-238.
8. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, et al. (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54: 2430-2435.
9. Muller I, Besta F, Schulz C, Massberg S, Schonig A, et al. (2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89: 783-787.
10. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, et al. (2004) Frequency of nonresponse antiplatelet activity of clopidogrel during pretreat-ment for cardiac catheterization. Am J Cardiol 93: 456-458.
11. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, et al. (2004) Clopidogrel resistance is associated with increased risk of recurrent athero-thrombotic events in patients with acute myocardial infarction. Circulation 109: 3171-3175.
12. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C, et al. (2005) Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 115: 101-108.
13. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, et al. (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38: 92-99.
14. Hulot JS, Bura A, Villard E, Azizi M, Remones V, et al. (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108: 2244-2247.
15. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, et al. (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5: 2429-2436.
16. Umemura K, Furuta T, Kondo K (2008) The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 6: 1439-1441.
17. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363-375.
18. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, et al. (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53: 849-856.
19. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, et al. (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56: 919-933.
20. Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, et al. (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17: 110-116.
21. Kreutz RP, Nystrom P, Kreutz Y, Miao J, Desta Z, et al. (2012) Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clin Pharmacol 4: 13-20.
22. Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, et al. (2011) No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 32: 1605-1613.
23. Pare G, Ross S, Mehta SR, Yusuf S, Anand SS, et al. (2012) Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. Circ Cardiovasc Genet 5: 250-256.
24. Marsillach J, Aragones G, Beltran R, Caballeria J, Pedro-Botet J, et al. (2009) The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem 42: 91-98.
25. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, et al. (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299: 1265-1276.
26. Mackness MI, Arrol S, Mackness B, Durrington PN (1997) Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 349: 851-852.
27. Lawlor DA, Day IN, Gaunt TR, Hinks LJ, Briggs PJ, et al. (2004) The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genet 5: 17.
28. Regieli JJ, Jukema JW, Doevendans PA, Zwinderman AH, Kastelein JJ, et al. (2009) Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J Am Coll Cardiol 54: 1238-1245.
29. Likidlilid A, Akrawinthawong K, Poldee S, Sriratanasathavorn C (2010) Paraoxonase 1 polymorphisms as the risk factor of coronary heart disease in a Thai population. Acta Cardiol 65: 681-691.
30. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, et al. (1998) The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141: 259-264.
31. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, et al. (2000) Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149: 435-442.
32. Ferre N, Tous M, Paul A, Zamora A, Vendrell JJ, et al. (2002) Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem 35: 197-203.
33. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52: 349-355.
34. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, et al. (2008) Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 99: 121-126.
35. Gerotziafas GT, Zarifis J, Bandi A, Mossialos L, Galea V, et al. (2012) Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry. Clin Appl Thromb Hemost 18: 356-363.
36. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, et al. (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269: 15419-15422.
37. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, et al. (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598.
38. Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Fontana L, et al. (2004) Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Exp Gerontol 39: 1089-1094.
39. Cordell HJ (2002) Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet 11: 2463-2468.
40. Schwender H, Fritsch A (2013) scrime: Analysis of High-Dimensional Categorical Data such as SNP Data. Available: http://CRAN.R-project.org/package=scrime.
41. R Core Team (2013) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available: http://www.R-project.org.
42. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302: 849-857.
43. Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, et al. (2010) Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 8: 1685-1693.
44. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, et al. (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119: 2553-2560.
45. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, et al. (2010) Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacoge-netic analysis. Lancet 376: 1312-1319.
46. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, et al. (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304: 1821-1830.
47. Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, et al. (2010) Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55: 2427-2434.
48. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, et al. (2008) Cytochrome P450 2C19 681G.A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51: 1925-1934.
49. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, et al. (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30: 916-922.
50. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, et al. (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373: 309-317.
51. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, et al. (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354-362.
52. Harmsze AM, van Werkum JW, Ten Berg JM, Zwart B, Bouman HJ, et al. (2010) CYP2C19∗2 and CYP2C9∗3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 31: 3046-3053.
53. Simon T, Steg PG, Becquemont L, Verstuyft C, Kotti S, et al. (2011) Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther 90: 561-567.
54. Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, et al. (2011) Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 4: 429-436.
55. Fontana P, James R, Barazer I, Berdague P, Schved JF, et al. (2011) Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost 9: 1664-1666.
56. Rideg O, Komocsi A, Magyarlaki T, Tokes-Fuzesi M, Miseta A, et al. (2011) Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics 12: 1269-1280.
57. Lewis JP, Fisch AS, Ryan K, O'Connell JR, Gibson Q, et al. (2011) Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther 90: 568-574.